PCSK9 and carbohydrate metabolism: A double-edged sword

doi:10.4239/wjd.v8.i7.311

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 7

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7837)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-2) series.

Item

Count

PDF

487

WORD

357

HTML

4089

Figures (1-2)

280

Tables (1-2)

306

Sum=5519

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

964

Download

1262

Sum=2226

Jul 15, 2017 (publication date) through Jan 22, 2025

Times Cited of This Article

Times Cited (16)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Diabetes. Jul 15, 2017; 8(7): 311-316
Published online Jul 15, 2017. doi: 10.4239/wjd.v8.i7.311

Open in New Tab Full Size Figure Download Figure

Figure 1 The effect of proprotein convertase subtilisin/kexin type 9 (A) and proprotein convertase subtilisin/kexin type 9 inhibition (B) on liver cells low-density lipoprotein receptors expression and serum low-density lipoprotein-cholesterol levels. PCSK9: Proprotein convertase subtilisin/kexin type 9; LDL: Low-density lipoprotein; LDLR: Low-density lipoprotein receptors.

Open in New Tab Full Size Figure Download Figure

Figure 2 The role of proprotein convertase subtilisin/kexin type 9 on carbohydrate homeostasis. Accordingly, PCSK9 inhibitors may be associated with a neutral effect on carbohydrate homeostasis at least in the short term. PCSK9: Proprotein convertase subtilisin/kexin type 9; LDL: Low-density lipoprotein; LDLR: LDL receptors; HbA1c: Glycated hemoglobin; SREBP-1C: Sterol regulatory element-binding protein I-C; HOMA-IR: Homeostasis model assessment-insulin resistance.

Citation: Filippatos TD, Filippas-Ntekouan S, Pappa E, Panagiotopoulou T, Tsimihodimos V, Elisaf MS. PCSK9 and carbohydrate metabolism: A double-edged sword. World J Diabetes 2017; 8(7): 311-316
URL: https://www.wjgnet.com/1948-9358/full/v8/i7/311.htm
DOI: https://dx.doi.org/10.4239/wjd.v8.i7.311